Showing 2461-2470 of 5798 results for "".
- La Fondation La Roche-Posay (North American) Awards 2020 Grant Winnershttps://practicaldermatology.com/news/la-fondation-la-roche-posay-north-american-awards-2020-grant-winners/2460363/And the five La Fondation La Roche-Posay (North America) 2020 research grant winners in the field of dermatology are… Dawn Zhang Eichenfield, MD, PhD, Chief Dermatology Resident at the University of California, San Diego. She received the first place pr
- Finacea Foam Back in Pharmacies: LEO Pharmahttps://practicaldermatology.com/news/finacea-foam-back-in-pharmacies-leo-pharma/2460347/After a shortage due to production delays, Finacea®(azelaic acid) Foam, 15% is now available, LEO Pharma says. Finacea Foam is the first and only prescription foam FDA approved for the treatment of rosacea. It is a light water-based (hydrophilic) foam that is alcohol-free and fragrance free.<
- Cynosure Names David Long Global Chief Financial Officerhttps://practicaldermatology.com/news/cynosure-names-david-long-global-chief-financial-officer/2460343/David Long is Cynosure’s new Chief Financial Officer, effective immediately. Until recently, Long served as CFO at Corindus Vascular Robotics, Inc., where he brought the company public and, ultimately, navigated its strategic sale to Siemens.
- Lessons from Italy: Understanding and Recognizing Potential Skin Manifestations in COVID-19https://practicaldermatology.com/news/lessons-from-italy-understanding-and-recognizing-potential-skin-manifestations-in-covid-10-1/2460340/Italian dermatologists report that about 20 percent of COVID-19 patients may develop skin manifestations including red rashes. Their findings appear in Journal of the European Academy of Dermatology Venereology. The researchers looked at skin in 148 COVID-19 patients
- Wontech Scores FDA Nod for Sandro Dual Laserhttps://practicaldermatology.com/news/wontech-scores-fda-nod-for-sandro-dual-laser/2460333/The U.S. Food and Drug Administration granted 510 (K) marketing clearance to Wontech’s Sandro Dual, a hybrid Nd:YAG & Alexandrite laser device. In the hybrid mode, by irradiating a short time difference between two wavelengths of 755nm and 1064nm, the laser accurately hits its
- FDA Approves Lilly's Taltz for Treatment Of Pediatric Patients with Psoriasishttps://practicaldermatology.com/news/fda-approves-lillys-taltz-for-treatment-of-pediatric-patients-with-psoriasis/2460327/The FDA has approved a supplemental Biologics License Application (sBLA) for Eli Lilly and Company's Taltz (ixekizumab) injection, 80 mg/mL for the treatment of pediatric patients (ages 6 to under 18) with moderate to severe plaque psoriasis who are c
- Industry Responds to COVID-19: Allergan Foundation; AG Hair; Revancehttps://practicaldermatology.com/news/industry-responds-to-covid-19-allergan-foundation-ag-hair-revance/2460326/Allergan. Of the approximately $13 million in charitable grants the Allergan Foundation has awarded in 2020, a total of $2 million will be dedicated to more than 70 organizations responding to the local impact of the COVID-19 pandemic. Other grant recipients i
- Telehealth Webinar from Cosmetic Surgery Forum Explores Best Practiceshttps://practicaldermatology.com/news/telehealth-webinar-available-from-cosmetic-surgery-forum/2460325/As dermatologists deal with the evolving COVID-19 crisis, they are increasingly searching for guidance on the proper use of telemedicine. Joel Schlessinger, MD, Founder of Cosmetic Surgery Forum, brought together George Hruza, MD, past president of the AAD, and Antoanella Calame, MD, founder of t
- FDA Greenlights Pfizer’s Eucrisa for Children As Young As Three Months With ADhttps://practicaldermatology.com/news/fda-greenlights-pfizers-eucrisa-for-children-as-young-as-three-months-with-ad/2460321/The U.S. Food and Drug Administration (FDA) gave its nod to Pfizer’s Eucrisa ointment, 2%, for children as young as age 3 months with mild-to-moderate atopic dermatitis (AD). Eucrisa was previously approved for use in adults and children 2 years of age and older. It is the first a
- Zylö Therapeutics a Finalist in the Buzz of BIO Contesthttps://practicaldermatology.com/news/zylo-therapeutics-a-finalist-in-the-buzz-of-bio-contest/2460311/Voting ends tonight for the Buzz of BIO contest, sponsored by BIO, the world's largest trade association representing biotechnology companies. Zylö Therapeutics, which has dermatology as one of its focus areas, is a finalist in the “Pipelines of Promise”